PE20242203A1 - Derivados de pirazolopiridina y sus usos - Google Patents

Derivados de pirazolopiridina y sus usos

Info

Publication number
PE20242203A1
PE20242203A1 PE2023002595A PE2023002595A PE20242203A1 PE 20242203 A1 PE20242203 A1 PE 20242203A1 PE 2023002595 A PE2023002595 A PE 2023002595A PE 2023002595 A PE2023002595 A PE 2023002595A PE 20242203 A1 PE20242203 A1 PE 20242203A1
Authority
PE
Peru
Prior art keywords
c6alkyl
hydrogen
compounds
halo
methyl
Prior art date
Application number
PE2023002595A
Other languages
English (en)
Spanish (es)
Inventor
Simone Bonazzi
Artiom Cernijenko
Jennifer Stroka Cobb
Natalie Alysia Dales
Janetta Dewhurst
Matthew James Hesse
Rama Jain
John Ryan Kerrigan
Hasnain Ahmed Malik
James R Manning
Gary O'brien
Andrew W Patterson
Noel Marie-France Thomsen
Pamela Yf Ting
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20242203A1 publication Critical patent/PE20242203A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PE2023002595A 2021-03-15 2022-03-14 Derivados de pirazolopiridina y sus usos PE20242203A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163161139P 2021-03-15 2021-03-15
US202163164130P 2021-03-22 2021-03-22
PCT/IB2022/052281 WO2022195454A1 (en) 2021-03-15 2022-03-14 Pyrazolopyridine derivatives and uses thereof

Publications (1)

Publication Number Publication Date
PE20242203A1 true PE20242203A1 (es) 2024-11-19

Family

ID=80819999

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023002595A PE20242203A1 (es) 2021-03-15 2022-03-14 Derivados de pirazolopiridina y sus usos

Country Status (20)

Country Link
US (4) US11787785B2 (cg-RX-API-DMAC7.html)
EP (1) EP4308562A1 (cg-RX-API-DMAC7.html)
JP (2) JP7659648B2 (cg-RX-API-DMAC7.html)
KR (1) KR102902295B1 (cg-RX-API-DMAC7.html)
AU (2) AU2022239950B2 (cg-RX-API-DMAC7.html)
CA (1) CA3208951A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023002726A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023013486A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230486A (cg-RX-API-DMAC7.html)
DO (1) DOP2023000188A (cg-RX-API-DMAC7.html)
EC (1) ECSP23076800A (cg-RX-API-DMAC7.html)
IL (1) IL305931A (cg-RX-API-DMAC7.html)
JO (1) JOP20230218A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023010827A (cg-RX-API-DMAC7.html)
PE (1) PE20242203A1 (cg-RX-API-DMAC7.html)
PY (1) PY2217419A (cg-RX-API-DMAC7.html)
TW (1) TWI923713B (cg-RX-API-DMAC7.html)
UY (1) UY39671A (cg-RX-API-DMAC7.html)
WO (1) WO2022195454A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202307290B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021255160B2 (en) 2020-04-13 2024-02-01 Aptabio Therapeutics Inc. Pulmonary fibrosis medicine containing pyrazole derivative
EP4308559A1 (en) * 2021-03-15 2024-01-24 Novartis AG Benzisoxazole derivatives and uses thereof
UY39671A (es) 2021-03-15 2022-10-31 Novartis Ag Derivados de pirazolopiridina y sus usos.
PE20240822A1 (es) 2021-03-22 2024-04-18 Neurocrine Biosciences Inc Inhibidores de vmat2 y metodos de uso
CN120129677A (zh) 2022-11-04 2025-06-10 百时美施贵宝公司 化合物及其用于治疗血红素病变的用途
WO2024255810A1 (en) * 2023-06-15 2024-12-19 Hangzhou Glubio Pharmaceutical Co., Ltd Dihydropyrimidine-2, 4 (1h, 3h) -dione-containing polycyclic derivatives and pharmaceutical composition thereof, preparation method thereof and use thereof
WO2026136866A1 (en) 2024-12-20 2026-06-25 Prelude Therapeutics Incorporated Kat6 targeting compounds

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
BRPI0417186A (pt) 2003-12-02 2007-03-06 Celgene Corp método de tratamento de um indivìduo tendo uma hemoglobinopatia ou uma anemia, de modulação da diferenciação de uma célula-tronco ou precursora de cd34+ para uma linhagem de eritróides, e, composição farmacêutica
EP1604988A1 (en) 2004-05-18 2005-12-14 Sanofi-Aventis Deutschland GmbH Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
CN102089291B (zh) 2008-04-28 2016-08-17 杏林制药株式会社 环戊基丙烯酰胺衍生物
EP2165707A1 (en) * 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
SG183257A1 (en) 2010-02-11 2012-09-27 Celgene Corp Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
ES2689429T3 (es) 2012-07-13 2018-11-14 Ucb Biopharma Sprl Derivados de imidazopiridina como moduladores de actividad de TNF
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
TWI793151B (zh) * 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
US11512080B2 (en) 2018-01-12 2022-11-29 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
JP2020009513A (ja) * 2018-07-10 2020-01-16 キオクシア株式会社 メモリシステム
AR116109A1 (es) * 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
EP3897631A4 (en) 2018-12-20 2022-11-23 C4 Therapeutics, Inc. TARGETED PROTEIN BREAKDOWN
KR102980990B1 (ko) 2019-04-05 2026-06-25 카이메라 쎄라퓨틱스 인코포레이티드 Stat 분해제 및 이의 용도
EP3969458A4 (en) 2019-05-13 2023-05-17 Borah, Inc. CHEMICAL COMPOUNDS
PH12022551482A1 (en) 2019-12-18 2023-11-29 Novartis Ag 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EP4100394B1 (en) 2020-02-04 2026-04-08 Stingray Therapeutics, Inc. Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (enpp1) and methods of use thereof
US20230089530A1 (en) 2020-02-09 2023-03-23 Newave Pharmaceutical Inc. Quinuclidinone analogues as anticancer agents
UY39671A (es) 2021-03-15 2022-10-31 Novartis Ag Derivados de pirazolopiridina y sus usos.

Also Published As

Publication number Publication date
ZA202307290B (en) 2024-09-25
JP7659648B2 (ja) 2025-04-09
TW202304900A (zh) 2023-02-01
AU2022239950B2 (en) 2024-09-12
AU2022239950A1 (en) 2023-08-31
MX2023010827A (es) 2023-09-28
CL2023002726A1 (es) 2024-04-01
BR112023018542A2 (pt) 2023-10-10
EP4308562A1 (en) 2024-01-24
US20250282762A1 (en) 2025-09-11
JP2024509981A (ja) 2024-03-05
AU2024278210A1 (en) 2025-01-02
UY39671A (es) 2022-10-31
CA3208951A1 (en) 2022-09-22
AU2024278210B2 (en) 2026-03-26
DOP2023000188A (es) 2023-11-15
PY2217419A (es) 2022-09-27
WO2022195454A1 (en) 2022-09-22
NZ802195A (en) 2025-10-31
IL305931A (en) 2023-11-01
JOP20230218A1 (ar) 2023-09-14
ECSP23076800A (es) 2023-11-30
KR102902295B1 (ko) 2025-12-23
US20250002479A1 (en) 2025-01-02
US20240158374A1 (en) 2024-05-16
US12172984B2 (en) 2024-12-24
CO2023013486A2 (es) 2023-11-10
KR20230156766A (ko) 2023-11-14
US11787785B2 (en) 2023-10-17
US12252482B2 (en) 2025-03-18
US20230108325A1 (en) 2023-04-06
TWI923713B (zh) 2026-05-01
CR20230486A (es) 2024-01-25
JP2025106341A (ja) 2025-07-15

Similar Documents

Publication Publication Date Title
BR112022003514A2 (pt) Degradadores bifuncionais de brd9 e seus métodos de uso
PE20242113A1 (es) Compuestos de quinolina como inhibidores de kras
CO2022015054A2 (es) [1,3]diazino[5,4-d]pirimidinas como inhibidores de her2
AR036604A1 (es) Derivados de 4-pirimidona 3-sustituida
DOP2021000198A (es) Compuestos y su uso en el tratamiento del cáncer
AR044543A1 (es) Derivados de pirazolo-quinazolina, un procedimiento para su preparacion y su uso como inhibidor de quinasa
MX2021006265A (es) Derivados de panteteina y usos de los mismos.
UY27248A1 (es) Derivados de pirazol
MX2023007140A (es) Compuestos farmaceuticos.
UY28578A1 (es) Derivados de amida
PE20240657A1 (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y sus usos medicos
MY208400A (en) Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (ror) and pharmaceutical uses thereof
AR107828A1 (es) 2-amino-n-[7-metoxi-2,3-dihidroimidazo-[1,2-c]quinazolin-5-il]pirimidin-5-carboxamidas como inhibidor de pi3k
PA8593301A1 (es) Derivados de 1-piperidin-4-il-4-pirrolidin-3-il-piperazina sustituidos y su uso como antagonistas de neuroquininas
PY2217419A (es) Derivados de pirazolopiridina y sus usos
AR040246A1 (es) Derivados de 1-piperazinilacilpiperidina substituidos, su preparacion y su aplicacion en terapeutica
AR049711A1 (es) Compuestos heterociclicos condensados como inhibidores de la aldosterona sintasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el hiperaldosterismo y por una liberacion excesiva de cortiso
AR045159A1 (es) Derivados de 1-sulfonilindoles, su preparacion y su aplicacion como medicamentos
CO2025001849A2 (es) Compuestos de imidazopiridina, preparación de los mismos y usos terapéuticos de los mismos
EA201992090A1 (ru) ДЕЙТЕРИРОВАННЫЕ СОЕДИНЕНИЯ ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА
PH12021551035A1 (en) Pyrazoles as modulators of hemoglobin
AR122156A1 (es) DERIVADOS DE PIRAZOLO[1,5-a]PIRIMIDINA QUE TIENEN ACTIVIDAD MULTIMODAL CONTRA EL DOLOR
DOP2025000099A (es) Enlazadores-cargas útiles de adc derivados de exatecán, composiciones farmacéuticas, y usos de los mismos
MX2023011377A (es) Derivados de ciclobutilo 1,3-sustituidos y sus usos.
PA8572601A1 (es) Compuestos de 3,4-dihidroquinolin-2 (1h)-ona como antagonistas del receptor nr2b